Elizabeth Holmes, pictured on November 18, is now incarcerated. Photo by Justin Sullivan/Getty Images

A longtime Houstonian is coming home — by way of prison.

Elizabeth Holmes, the disgraced founder of blood-testing startup Theranos, reported to F.P.C. Bryan, on Tuesday, May 30, per multiple news outlets. She is set to serve 11 years and three months in the women's minimum-security prison located some 90 minutes from Houston hometown.

According to the the New York Times, the onetime Tanglewood resident arrived at the prison in a Ford Expedition that appeared to be driven by her mother, Noel Holmes. Her father, Christian Holmes, appeared to be inside.

The Times adds that after some shuffling around, out of the view of the cameras gathered nearby, Holmes entered the facility wearing jeans, glasses and a sweater, and carrying some papers.

Prior to her arrival in Bryan, Holmes, 39, spent Memorial Day weekend with her family on the beach near her oceanfront San Diego home with her partner Billy Evans and their two children, according to the Daily Mail.

As CultureMap previously reported, Holmes was sentenced to more than 11 years in prison on November 18, 2002 in San Jose, California following her conviction in January that year for defrauding Theranos investors.

Actress Amanda Seyfried, who played Holmes in the Hulu series The Dropout, shared her thoughts on the woman she portrayed to great acclaim. “Life’s not fair,” Seyfried noted on Good Morning America on Tuesday, “but in a lot of ways, it’s fair. For her, in particular.”

Thrust into the spotlight as the new face of white-collar, Silicon Valley fraud, Holmes now serves as a warning to those who might consider a similar path, her sentencing judge made clear.

“I suppose we step back and ask what is the pathology of fraud? Is it the refusal to accept responsibility or express contrition in any way?" Judge Edward Davila said during the ruling, according to Yahoo! Finance. "Perhaps that is the cautionary tale that will go forward from this case."

Davila ordered Holmes to turn herself into custody on April 27, 2023.

Specifically, Holmes' sentence is 11 years and three months in prison, with another three years of supervision after release. Additionally, Holmes and her ex-boyfriend and former Theranos COO Ramesh “Sunny” Balwani have been ordered to pay $452 million to their fraud victims.

Once compared to disruptors and innovators Steve Jobs and Bill Gates, Holmes rose to fame by enticing investors with the promise that her Theranos could run hundreds of blood tests via a simple pin prick. Buzz for Theranos grew to the point that Theranos was valued at $9 billion, which made Holmes the world’s first self-made female billionaire.

Yet, after securing more than $900 million in funding, Theranos was proven to be essentially bogus by the Wall Street Journal in 2015.

Facing up to 20 years in prison, a tearful Holmes, who is pregnant, addressed the court. "I stand before you taking responsibility for Theranos," she said, per Yahoo. "I loved Theranos. It was my life’s work. My team meant the world to me. They wanted to make a difference in the world. I am devastated by my failings," she said. "Every day for the past years, I have felt deep pain for the people…those people who believe in us and those patients. I worked so hard to serve. I gave everything I had to try to to build...Theranos. Looking back, there are so many things I would do differently. I tried to realize my dream too quickly."

Holmes is the subject of the aforementioned series, The Dropout, which centers on her early life in Houston, where she grew up in Tanglewood and attended St. John's School. Her father's layoff from Enron is presented as clearly an inciting incident in her life. As The Dropout depicts, Holmes would meet boyfriend/partner Ramesh "Sunny" Balwani, drop out of Stanford, and launch Theranos.

One of the most memorable lines in the miniseries comes when a young Holmes plainly states her goals at a family gathering. "I wanna be a billionaire," she said plainly — a memorable and clearly prophetic statement.

------

This article originally ran on CultureMap.

Former Houstonian Elizabeth Holmes had her day in court on November 18. Photo by Justin Sullivan/Getty Images

Disgraced Theranos CEO and former Houstonian Elizabeth Holmes sentenced to 11 years for fraud

convicted and sentenced

A former Houstonian who became the face of recent white-collar, Silicon Valley fraud case is facing more than a decade in prison.

Elizabeth Holmes, founder of blood-testing startup Theranos, was sentenced to more than 11 years in prison on Friday, November 18 in San Jose, California. The sentencing comes her conviction in January for defrauding Theranos investors.

“I suppose we step back and ask what is the pathology of fraud? Is it the refusal to accept responsibility or express contrition in any way?" Judge Edward Davila said during the ruling, according to Yahoo! Finance. "Perhaps that is the cautionary tale that will go forward from this case."

Specifically, Holmes' sentence is 11 years and three months in prison, with another three years of supervision after release. Additionally, Holmes faces a fine of $400 million to be paid at a later date. Davila ordered Holmes, who is widely expected to appeal her sentence, to turn herself into custody on April 27, 2023.

Once compared to disruptors and innovators Steve Jobs and Bill Gates, Holmes rose to fame by enticing investors with the promise that her Theranos could run hundreds of blood tests via a simple pin prick. Buzz for Theranos grew to the point that Theranos was valued at $9 billion, which made Holmes the world’s first self-made female billionaire.

Yet, after securing more than $900 million in funding, Theranos was proven to be essentially bogus by the Wall Street Journal in 2015.

Facing up to 20 years in prison, a tearful Holmes, who is pregnant, addressed the court. "I stand before you taking responsibility for Theranos," she said, per Yahoo. "I loved Theranos. It was my life’s work. My team meant the world to me. They wanted to make a difference in the world. I am devastated by my failings," she said. "Every day for the past years, I have felt deep pain for the people…those people who believe in us and those patients. I worked so hard to serve. I gave everything I had to try to to build...Theranos. Looking back, there are so many things I would do differently. I tried to realize my dream too quickly."

Holmes is the subject of a Hulu documentary, The Dropout, which centers on her early life in Houston, where she grew up in Tanglewood and attended St. John's School. Her father's layoff from Enron is presented as clearly an inciting incident in her life. As The Dropout depicts, Holmes would meet boyfriend/partner Ramesh "Sunny" Balwani, drop out of Stanford, and launch Theranos.

One of the most memorable lines in the miniseries comes when a young Holmes plainly states her goals at a family gathering. "I wanna be a billionaire," she said plainly — a memorable and clearly prophetic statement.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.